Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q3 2018 · 10-Q
Revenue$173.70M$173.70M+16.3% vs Q3 2017 Net Income$20.90M$20.90M−37.7% vs Q3 2017 EPS Diluted$0.41$0.41−39.7% vs Q3 2017 Gross Profit$21,300,000−55.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
Operating Cash Flowderived$174,000,000+398.0% Free Cash Flowderived$147,900,000+567.3% Margins · derivedGross margin12.3%−19.7 pt vs Q3 2017
Operating margin12.3%−19.7 pt vs Q3 2017
Net margin12.0%−10.4 pt vs Q3 2017
ended Sep 30, 2018 · filed Nov 2, 2018 · 33 d after period end